What is Zacks Research’s Forecast for MD Q1 Earnings?

Pediatrix Medical Group, Inc. (NYSE:MD) – Stock analysts at Zacks Research boosted their Q1 2026 earnings estimates for shares of Pediatrix Medical Group in a report issued on Monday, November 24th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.29 for the quarter, up from their prior forecast of $0.28. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Pediatrix Medical Group’s current full-year earnings is $1.38 per share. Zacks Research also issued estimates for Pediatrix Medical Group’s Q2 2026 earnings at $0.43 EPS, Q3 2026 earnings at $0.45 EPS, Q4 2026 earnings at $0.47 EPS and FY2027 earnings at $1.61 EPS.

Several other equities analysts also recently issued reports on the company. UBS Group lifted their price objective on Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Truist Financial increased their target price on Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Leerink Partners lifted their price target on Pediatrix Medical Group from $14.50 to $17.00 and gave the company a “market perform” rating in a report on Friday, September 5th. Wall Street Zen upgraded shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 4th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $21.00.

Pediatrix Medical Group Stock Up 3.1%

Shares of MD opened at $23.82 on Tuesday. The company has a market capitalization of $2.05 billion, a P/E ratio of 18.46 and a beta of 1.20. Pediatrix Medical Group has a one year low of $11.84 and a one year high of $24.02. The business’s 50 day simple moving average is $18.62 and its 200-day simple moving average is $15.91. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.80 and a quick ratio of 1.80.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.21. The firm had revenue of $492.88 million for the quarter, compared to analysts’ expectations of $476.45 million. Pediatrix Medical Group had a net margin of 5.66% and a return on equity of 18.94%. The company’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.44 earnings per share.

Institutional Trading of Pediatrix Medical Group

A number of institutional investors have recently bought and sold shares of MD. Marshall & Sullivan Inc. WA acquired a new position in shares of Pediatrix Medical Group in the 2nd quarter valued at $41,000. Canada Pension Plan Investment Board bought a new stake in Pediatrix Medical Group in the second quarter valued at about $83,000. AlphaQuest LLC lifted its stake in Pediatrix Medical Group by 16.0% in the first quarter. AlphaQuest LLC now owns 5,877 shares of the company’s stock valued at $85,000 after buying an additional 811 shares during the period. Smartleaf Asset Management LLC lifted its stake in Pediatrix Medical Group by 10.6% in the third quarter. Smartleaf Asset Management LLC now owns 6,250 shares of the company’s stock valued at $101,000 after buying an additional 601 shares during the period. Finally, Quantbot Technologies LP bought a new position in Pediatrix Medical Group during the second quarter worth about $99,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Insider Transactions at Pediatrix Medical Group

In other news, Director Michael A. Rucker sold 10,478 shares of Pediatrix Medical Group stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $23.00, for a total transaction of $240,994.00. Following the completion of the sale, the director owned 59,101 shares in the company, valued at $1,359,323. The trade was a 15.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Laura A. Linynsky sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $21.65, for a total transaction of $216,500.00. Following the sale, the director directly owned 32,232 shares of the company’s stock, valued at approximately $697,822.80. This trade represents a 23.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.90% of the stock is owned by company insiders.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.